394 related articles for article (PubMed ID: 35320578)
1. Application of Meta-analysis to Evaluate Relationships Among ARIA-E Rate, Amyloid Reduction Rate, and Clinical Cognitive Response in Amyloid Therapeutic Clinical Trials for Early Alzheimer's Disease.
Wang D; Kowalewski EK; Koch G
Ther Innov Regul Sci; 2022 May; 56(3):501-516. PubMed ID: 35320578
[TBL] [Abstract][Full Text] [Related]
2. Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer's Disease: A Systematic Review and Network Meta-Analysis.
Qiao Y; Gu J; Yu M; Chi Y; Ma Y
CNS Drugs; 2024 Mar; 38(3):169-192. PubMed ID: 38429615
[TBL] [Abstract][Full Text] [Related]
3. Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.
Bateman RJ; Smith J; Donohue MC; Delmar P; Abbas R; Salloway S; Wojtowicz J; Blennow K; Bittner T; Black SE; Klein G; Boada M; Grimmer T; Tamaoka A; Perry RJ; Turner RS; Watson D; Woodward M; Thanasopoulou A; Lane C; Baudler M; Fox NC; Cummings JL; Fontoura P; Doody RS;
N Engl J Med; 2023 Nov; 389(20):1862-1876. PubMed ID: 37966285
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of anti-amyloid-β monoclonal antibodies in current Alzheimer's disease phase III clinical trials: A systematic review and interactive web app-based meta-analysis.
Jeremic D; Navarro-López JD; Jiménez-Díaz L
Ageing Res Rev; 2023 Sep; 90():102012. PubMed ID: 37423541
[TBL] [Abstract][Full Text] [Related]
5. Clinically Important Benefits and Harms of Monoclonal Antibodies Targeting Amyloid for the Treatment of Alzheimer Disease: A Systematic Review and Meta-Analysis.
Ebell MH; Barry HC; Baduni K; Grasso G
Ann Fam Med; 2024; 22(1):50-62. PubMed ID: 38253509
[TBL] [Abstract][Full Text] [Related]
6. High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects.
Villain N; Planche V; Levy R
Rev Neurol (Paris); 2022 Dec; 178(10):1011-1030. PubMed ID: 36184326
[TBL] [Abstract][Full Text] [Related]
7. Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer's disease: A systematic review.
Chowdhury S; Chowdhury NS
Int J Immunopathol Pharmacol; 2023; 37():3946320231209839. PubMed ID: 37902139
[TBL] [Abstract][Full Text] [Related]
8. Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer's Disease Treated with Anti-Amyloid Beta Therapy.
Barakos J; Purcell D; Suhy J; Chalkias S; Burkett P; Marsica Grassi C; Castrillo-Viguera C; Rubino I; Vijverberg E
J Prev Alzheimers Dis; 2022; 9(2):211-220. PubMed ID: 35542992
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
Swanson CJ; Zhang Y; Dhadda S; Wang J; Kaplow J; Lai RYK; Lannfelt L; Bradley H; Rabe M; Koyama A; Reyderman L; Berry DA; Berry S; Gordon R; Kramer LD; Cummings JL
Alzheimers Res Ther; 2021 Apr; 13(1):80. PubMed ID: 33865446
[TBL] [Abstract][Full Text] [Related]
10. The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials.
Wu W; Ji Y; Wang Z; Wu X; Li J; Gu F; Chen Z; Wang Z
Eur J Med Res; 2023 Nov; 28(1):544. PubMed ID: 38017568
[TBL] [Abstract][Full Text] [Related]
11. Lecanemab in Early Alzheimer's Disease.
van Dyck CH; Swanson CJ; Aisen P; Bateman RJ; Chen C; Gee M; Kanekiyo M; Li D; Reyderman L; Cohen S; Froelich L; Katayama S; Sabbagh M; Vellas B; Watson D; Dhadda S; Irizarry M; Kramer LD; Iwatsubo T
N Engl J Med; 2023 Jan; 388(1):9-21. PubMed ID: 36449413
[TBL] [Abstract][Full Text] [Related]
12. Gantenerumab for early Alzheimer's disease: a systematic review and meta-analysis.
Menegaz de Almeida A; Leite M; Lopes LM; Gomes Lima P; Siegloch Barros ML; Rocha Pinheiro S; Andrade Í; Viana P; Morbach V; Marinheiro G; de Oliveira R; Pinheiro AC
Expert Rev Neurother; 2024 Jun; ():1-8. PubMed ID: 38879828
[TBL] [Abstract][Full Text] [Related]
13. Amyloid-Related Imaging Abnormalities (ARIA) in Immunotherapy Trials for Alzheimer's Disease: Need for Prognostic Biomarkers?
Piazza F; Winblad B
J Alzheimers Dis; 2016 Mar; 52(2):417-20. PubMed ID: 27031492
[TBL] [Abstract][Full Text] [Related]
14. Subcortical signal alteration of corticospinal tracts. A radiologic manifestation of ARIA: A case report.
Sotoudeh H; Alizadeh M; Shahidi R; Shobeiri P; Love N; Singhal A
Radiol Case Rep; 2023 Jan; 18(1):275-279. PubMed ID: 36388611
[TBL] [Abstract][Full Text] [Related]
15. Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer's disease.
Avgerinos KI; Ferrucci L; Kapogiannis D
Ageing Res Rev; 2021 Jul; 68():101339. PubMed ID: 33831607
[TBL] [Abstract][Full Text] [Related]
16. Donanemab in Early Alzheimer's Disease.
Mintun MA; Lo AC; Duggan Evans C; Wessels AM; Ardayfio PA; Andersen SW; Shcherbinin S; Sparks J; Sims JR; Brys M; Apostolova LG; Salloway SP; Skovronsky DM
N Engl J Med; 2021 May; 384(18):1691-1704. PubMed ID: 33720637
[TBL] [Abstract][Full Text] [Related]
17. At-Home Administration of Gantenerumab by Care Partners to People with Early Alzheimer's Disease: Feasibility, Safety and Pharmacodynamic Impact.
Boess FG; Scelsi MA; Grimmer T; Perry RJ; Tonietto M; Klein G; Hofmann C; Salami M; Wojtowicz J; Lansdall CJ; Lane C; Kerchner GA; Smith J; Doody RS
J Prev Alzheimers Dis; 2024; 11(3):537-548. PubMed ID: 38706270
[TBL] [Abstract][Full Text] [Related]
18. Amyloid-Related Imaging Abnormalities With Anti-amyloid Antibodies for the Treatment of Dementia Due to Alzheimer's Disease.
Withington CG; Turner RS
Front Neurol; 2022; 13():862369. PubMed ID: 35401412
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of anti-amyloid-ß monoclonal antibody therapy in early Alzheimer's disease: a systematic review and meta-analysis.
Dantas JM; Mutarelli A; Navalha DDP; Dagostin CS; Romeiro PHCL; Felix N; Nogueira A; Batista S; Teixeira L; Caramelli P
Neurol Sci; 2024 Jun; 45(6):2461-2469. PubMed ID: 37978096
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of lecanemab for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials.
Qiao Y; Chi Y; Zhang Q; Ma Y
Front Aging Neurosci; 2023; 15():1169499. PubMed ID: 37213538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]